PC9 and A549 human NSCLC cells were selected for their unique genetic pre-determinants of response: The former is characterized by low DNA-damage repair protein ERCC1 expression and a mutation in EGFR (15 bp del of exon 19), with both characteristics independently capable of sensitizing cells to platinum-based therapies [20], [21]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.